BACKGROUND: Chronic obstructive pulmonary disease (COPD) is increasingly considered a heterogeneous condition. It was hypothesised that COPD, as currently defined, includes different clinically relevant subtypes. METHODS: To identify and validate COPD subtypes, 342 subjects hospitalised for the first time because of a COPD exacerbation were recruited. Three months after discharge, when clinically stable, symptoms and quality of life, lung function, exercise capacity, nutritional status, biomarkers of systemic and bronchial inflammation, sputum microbiology, CT of the thorax and echocardiography were assessed. COPD groups were identified by partitioning cluster analysis and validated prospectively against cause-specific hospitalisations and all-cause mortality during a 4 year follow-up. RESULTS: Three COPD groups were identified: group 1 (n=126, 67 years) was characterised by severe airflow limitation (postbronchodilator forced expiratory volume in 1 s (FEV(1)) 38% predicted) and worse performance in most of the respiratory domains of the disease; group 2 (n=125, 69 years) showed milder airflow limitation (FEV(1) 63% predicted); and group 3 (n=91, 67 years) combined a similarly milder airflow limitation (FEV(1) 58% predicted) with a high proportion of obesity, cardiovascular disorders, diabetes and systemic inflammation. During follow-up, group 1 had more frequent hospitalisations due to COPD (HR 3.28, p<0.001) and higher all-cause mortality (HR 2.36, p=0.018) than the other two groups, whereas group 3 had more admissions due to cardiovascular disease (HR 2.87, p=0.014). CONCLUSIONS: In patients with COPD recruited at their first hospitalisation, three different COPD subtypes were identified and prospectively validated: 'severe respiratory COPD', 'moderate respiratory COPD', and 'systemic COPD'.
BACKGROUND:Chronic obstructive pulmonary disease (COPD) is increasingly considered a heterogeneous condition. It was hypothesised that COPD, as currently defined, includes different clinically relevant subtypes. METHODS: To identify and validate COPD subtypes, 342 subjects hospitalised for the first time because of a COPD exacerbation were recruited. Three months after discharge, when clinically stable, symptoms and quality of life, lung function, exercise capacity, nutritional status, biomarkers of systemic and bronchial inflammation, sputum microbiology, CT of the thorax and echocardiography were assessed. COPD groups were identified by partitioning cluster analysis and validated prospectively against cause-specific hospitalisations and all-cause mortality during a 4 year follow-up. RESULTS: Three COPD groups were identified: group 1 (n=126, 67 years) was characterised by severe airflow limitation (postbronchodilator forced expiratory volume in 1 s (FEV(1)) 38% predicted) and worse performance in most of the respiratory domains of the disease; group 2 (n=125, 69 years) showed milder airflow limitation (FEV(1) 63% predicted); and group 3 (n=91, 67 years) combined a similarly milder airflow limitation (FEV(1) 58% predicted) with a high proportion of obesity, cardiovascular disorders, diabetes and systemic inflammation. During follow-up, group 1 had more frequent hospitalisations due to COPD (HR 3.28, p<0.001) and higher all-cause mortality (HR 2.36, p=0.018) than the other two groups, whereas group 3 had more admissions due to cardiovascular disease (HR 2.87, p=0.014). CONCLUSIONS: In patients with COPD recruited at their first hospitalisation, three different COPD subtypes were identified and prospectively validated: 'severe respiratory COPD', 'moderate respiratory COPD', and 'systemic COPD'.
Authors: Jin Hwa Lee; Michael H Cho; Merry-Lynn N McDonald; Craig P Hersh; Peter J Castaldi; James D Crapo; Emily S Wan; Jennifer G Dy; Yale Chang; Elizabeth A Regan; Megan Hardin; Dawn L DeMeo; Edwin K Silverman Journal: Respir Med Date: 2014-08-11 Impact factor: 3.415
Authors: Peter J Castaldi; Marta Benet; Hans Petersen; Nicholas Rafaels; James Finigan; Matteo Paoletti; H Marike Boezen; Judith M Vonk; Russell Bowler; Massimo Pistolesi; Milo A Puhan; Josep Anto; Els Wauters; Diether Lambrechts; Wim Janssens; Francesca Bigazzi; Gianna Camiciottoli; Michael H Cho; Craig P Hersh; Kathleen Barnes; Stephen Rennard; Meher Preethi Boorgula; Jennifer Dy; Nadia N Hansel; James D Crapo; Yohannes Tesfaigzi; Alvar Agusti; Edwin K Silverman; Judith Garcia-Aymerich Journal: Thorax Date: 2017-06-21 Impact factor: 9.139
Authors: Peter J Castaldi; Jennifer Dy; James Ross; Yale Chang; George R Washko; Douglas Curran-Everett; Andre Williams; David A Lynch; Barry J Make; James D Crapo; Russ P Bowler; Elizabeth A Regan; John E Hokanson; Greg L Kinney; Meilan K Han; Xavier Soler; Joseph W Ramsdell; R Graham Barr; Marilyn Foreman; Edwin van Beek; Richard Casaburi; Gerald J Criner; Sharon M Lutz; Steven I Rennard; Stephanie Santorico; Frank C Sciurba; Dawn L DeMeo; Craig P Hersh; Edwin K Silverman; Michael H Cho Journal: Thorax Date: 2014-02-21 Impact factor: 9.139
Authors: Melissa C Friesen; Susan M Shortreed; David C Wheeler; Igor Burstyn; Roel Vermeulen; Anjoeka Pronk; Joanne S Colt; Dalsu Baris; Margaret R Karagas; Molly Schwenn; Alison Johnson; Karla R Armenti; Debra T Silverman; Kai Yu Journal: Ann Occup Hyg Date: 2014-12-03
Authors: Diego J Maselli; Surya P Bhatt; Antonio Anzueto; Russell P Bowler; Dawn L DeMeo; Alejandro A Diaz; Mark T Dransfield; Ashraf Fawzy; Marilyn G Foreman; Nicola A Hanania; Craig P Hersh; Victor Kim; Gregory L Kinney; Nirupama Putcha; Emily S Wan; J Michael Wells; Gloria E Westney; Kendra A Young; Edwin K Silverman; MeiLan K Han; Barry J Make Journal: Chest Date: 2019-05-30 Impact factor: 9.410
Authors: Miguel J Divo; Carlos Cabrera; Ciro Casanova; Jose M Marin; Victor M Pinto-Plata; Juan P de-Torres; Javier Zulueta; Jorge Zagaceta; Pablo Sanchez-Salcedo; Juan Berto; Claudia Cote; Bartolome R Celli Journal: Chronic Obstr Pulm Dis Date: 2014-09-25